List of Excipients in Branded Drug NORGESTREL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Walgreen Company	NORGESTREL	norgestrel	0363-5510	FD&C YELLOW NO. 5	2026-07-13
Walgreen Company	NORGESTREL	norgestrel	0363-5510	LACTOSE	2026-07-13
Walgreen Company	NORGESTREL	norgestrel	0363-5510	MAGNESIUM STEARATE	2026-07-13

Norgestrel Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Norgestrel is a mature synthetic progestin with limited active-ingredient patent protection and no meaningful biosimilar barrier. The main commercial opportunities are in low-cost, high-quality oral solid dosage forms, over-the-counter access, private-label products, improved excipient systems, and global supply optimization. Perrigo’s Opill, a 0.075 mg norgestrel tablet, is the leading U.S. benchmark after FDA approval for nonprescription use in 2023.[1]

What is norgestrel and which products contain it?

Norgestrel is a racemic mixture containing levonorgestrel and its less active stereoisomer. It is used primarily as an oral progestin contraceptive. The U.S. prescription product marketed as Opill contains 0.075 mg of norgestrel per tablet and is taken once daily without a hormone-free interval.[1]

Norgestrel differs from levonorgestrel products in regulatory and formulation strategy:

Attribute	Norgestrel	Levonorgestrel
Active ingredient	Racemic progestin mixture	Single active stereoisomer
U.S. Opill dose	0.075 mg	Not applicable
Primary use	Progestin-only oral contraception	Emergency contraception and combination contraception
U.S. OTC product	Opill	Plan B and generic products for emergency contraception
Patent position	Mature, largely commoditized	Mature, largely commoditized
Main development barrier	Content uniformity, dissolution, labeling, distribution	Same, with different dose and use instructions
Biosimilar exposure	None	None

Norgestrel is a small-molecule drug. Biosimilar competition does not apply. Competition will arise through generic, authorized-generic, private-label, and alternative hormonal contraceptive products.

What excipients are used in the Opill norgestrel tablet?

The current U.S. Opill labeling lists colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch, and sodium starch glycolate as inactive ingredients.[1]

These excipients support a conventional immediate-release tablet platform:

Excipient	Primary formulation function	Commercial significance
Lactose monohydrate	Diluent and compression aid	Low cost, broad global supply, potential suitability limits for lactose-sensitive formulations
Microcrystalline cellulose	Diluent, dry binder, compaction aid	Supports direct compression and robust tablet hardness
Pregelatinized starch	Binder and disintegrant	Helps balance mechanical strength and rapid breakup
Sodium starch glycolate	Superdisintegrant	Supports immediate release at very low drug loading
Colloidal silicon dioxide	Glidant and flow aid	Reduces powder-flow variability in low-dose blends
Magnesium stearate	Lubricant	Controls ejection force but can slow wetting or dissolution if overmixed

The formulation problem is not total drug loading. It is distribution of 75 micrograms of active ingredient through a relatively large excipient blend. Small changes in powder flow, segregation, lubricant mixing, or compression can affect assay uniformity and content uniformity.

What excipient strategy is appropriate for low-dose norgestrel?

A direct-compression platform is the most commercially practical starting point. It minimizes processing steps, reduces solvent and drying requirements, and fits high-volume contraceptive manufacturing.

Content uniformity controls

Norgestrel requires a controlled blending strategy because the active represents only a small fraction of tablet mass. Key controls include:

• Particle-size matching between norgestrel and the principal diluent.
• Ordered addition of the active to a preblend containing a portion of microcrystalline cellulose or lactose.
• Low-shear geometric dilution before full-scale blending.
• Validated blend and tablet sampling plans.
• Control of hopper residence time and tablet press feed-frame conditions.
• Segregation testing after transfer, compression, and bulk handling.

A premix or granulated active concentrate can improve uniformity. The tradeoff is higher manufacturing cost and a greater process-validation burden.

Direct compression versus granulation

Platform	Advantages	Risks	Best commercial use
Direct compression	Lowest cost, short process, no drying	Segregation, flow variability, sensitivity to excipient grade	High-volume generic or private-label product
Dry granulation	Improves flow and blend uniformity without water	Roller-compaction impact on dissolution and densification	Formulations with poor flow or blend segregation
Wet granulation	Strong control of particle distribution and compression	Higher cost, moisture exposure, longer process	Products requiring robust manufacturing at scale
Spray-dried or engineered excipients	Better flow and uniformity potential	Higher material cost, limited supplier base	Premium or differentiated low-dose product

The reference-style excipient system used for Opill is commercially efficient. A challenger would need a measurable advantage before replacing it. The strongest targets are improved content uniformity, reduced tablet size, lower friability, improved moisture stability, or easier scale-up.

Lubricant and dissolution management

Magnesium stearate concentration and mixing time require tight control. Excessive lubrication can create hydrophobic particle surfaces and delay disintegration or dissolution. Sodium starch glycolate and pregelatinized starch can offset some of that effect, but the balance must be established through comparative dissolution testing.

Alternative lubricants, including sodium stearyl fumarate, may support faster wetting or reduce over-lubrication sensitivity. They can also increase cost, require new supplier qualification, and create a different regulatory justification. The opportunity is strongest where a formulation must meet aggressive dissolution specifications or operate across multiple manufacturing sites.

What formulation patents protect norgestrel products?

Norgestrel has no evident current composition-of-matter patent barrier in the United States. The active ingredient and conventional oral contraceptive formulations were developed decades ago. Any original patents covering norgestrel, early combination products, or basic tablet compositions have expired.

Current protection is more likely to involve:

• Product-specific formulation patents, if any remain active.
• Manufacturing-process patents.
• Packaging or stability-related inventions.
• Method-of-use patents tied to specific patient populations or dosing regimens.
• Regulatory exclusivity connected to clinical data or an Rx-to-OTC switch.

For a conventional immediate-release norgestrel tablet, patent risk is substantially lower than formulation-development and regulatory-compliance risk. A company seeking market entry should distinguish between an active patent claim, an Orange Book listing, and ordinary trade-secret protection around manufacturing parameters.

What is the FDA and Orange Book status of norgestrel?

FDA approved Opill for nonprescription use in July 2023, making it the first U.S. daily oral contraceptive approved for OTC use.[2] Perrigo began commercial U.S. availability in 2024 through retail and online channels.[3]

The relevant product history is:

Milestone	Date
Norgestrel prescription use in the United States	Established decades before OTC conversion
FDA approval of Opill for OTC use	July 13, 2023
Commercial U.S. launch of Opill	2024
Administration	FDA Center for Drug Evaluation and Research
Dosage form	Oral tablet
Strength	0.075 mg norgestrel

The Orange Book remains relevant for approved prescription versions, approved drug applications, patent listings, and exclusivity. OTC status changes distribution and labeling requirements, but it does not recreate new chemical entity exclusivity for a mature active ingredient.[4]

A company developing a generic or alternative norgestrel product would need to assess:

• The current approved application and reference product.
• Any listed patents associated with the relevant drug application.
• Whether an abbreviated new drug application or another pathway is available.
• Whether the proposed product will be prescription-only or OTC.
• Labeling, consumer comprehension, and nonprescription-use requirements.
• State and federal distribution rules for contraceptive products.

When does norgestrel lose exclusivity?

Norgestrel’s original chemical and basic product exclusivity expired long ago. The commercial exclusivity of the current U.S. OTC product depends more on regulatory status, brand recognition, manufacturing scale, and distribution than on a long-lived patent estate.

Opill does not receive new chemical entity exclusivity because norgestrel is not a new active ingredient. Any exclusivity tied to clinical investigations or regulatory supplements would be narrower than NCE exclusivity and would not necessarily prevent all competing norgestrel products.

The practical conclusion is that norgestrel is open to competition from a patent perspective, subject to application-specific patents, regulatory exclusivity, and FDA approval requirements.

Which companies are challenging or competing with norgestrel?

The competitive field has three layers.

Direct norgestrel competition

Perrigo is the principal U.S. commercial supplier through Opill. The product’s OTC status creates a first-mover advantage in consumer awareness and retail placement.

Future competitors could include:

• Generic-drug manufacturers filing abbreviated applications.
• Contract manufacturers supplying private-label oral contraceptives.
• Consumer-health companies seeking OTC contraceptive brands.
• International manufacturers exporting approved or locally registered norgestrel products.
• Authorized-generic suppliers using an equivalent formulation and supply chain.

No major public U.S. Paragraph IV litigation campaign against Opill is established in the available public record. A Paragraph IV filing would require a generic applicant to certify that listed patents are invalid, unenforceable, or not infringed. Because norgestrel is mature, the litigation exposure is more likely to involve product-specific patents than the active ingredient itself.

Indirect hormonal competition

Norgestrel competes with:

• Levonorgestrel emergency contraception.
• Progestin-only pills containing norethindrone or drospirenone.
• Combined oral contraceptives containing estrogen and progestin.
• Long-acting reversible contraceptives.
• Transdermal and vaginal delivery systems.

The relevant commercial comparison is not limited to chemical equivalence. Retail availability, consumer instructions, adherence requirements, side-effect profiles, and insurance coverage influence demand.

What are the commercial opportunities for norgestrel excipients?

The most attractive opportunities are cost reduction and manufacturing reliability rather than a highly differentiated therapeutic profile.

Excipient substitution

Excipient suppliers can target:

• Co-processed microcrystalline cellulose and starch systems.
• Low-moisture lactose grades.
• Higher-flow direct-compression lactose.
• Low-peroxide and low-metal excipient grades.
• Alternative superdisintegrants.
• Sodium stearyl fumarate or other lubricant systems.
• Functional excipient premixes designed for low-dose APIs.

A successful substitution must preserve assay uniformity, tablet hardness, friability, disintegration, dissolution, stability, and bioequivalence. Excipients with higher unit cost can still be attractive if they reduce rejected batches, shorten blending time, or permit smaller tablets.

OTC-oriented formulation and packaging

The OTC market creates opportunities beyond the tablet core:

• Unit-dose blister packaging.
• Child-resistant and senior-friendly package designs.
• Moisture-barrier blister materials.
• Calendar packaging to support daily adherence.
• Packaging compatible with e-commerce fulfillment.
• Multilingual instructions.
• Consumer labeling optimized for self-selection and missed-dose management.

Because norgestrel is used daily, packaging can affect adherence and repeat purchase. A formulation that is chemically equivalent but easier to identify and use may gain retail value.

Global supply-chain opportunities

Norgestrel tablets are suitable for manufacturing in multiple regions, subject to local registration and quality requirements. Commercial advantages may come from:

• Dual-source excipient qualification.
• Regional compression and packaging sites.
• Local API supply agreements.
• Reduced dependence on a single lactose or cellulose supplier.
• Standardized platform formulations across countries.
• Stability packages designed for hot and humid climates.

The lowest-risk strategy is a platform based on broadly compendial excipients with multiple qualified suppliers. Proprietary excipient systems can create differentiation but may introduce supply and regulatory dependencies.

How strong is the norgestrel patent estate?

The patent estate is weak for the active ingredient and conventional immediate-release tablet. It is stronger only where a company can establish a narrow, enforceable claim around a specific formulation, process, package, or use.

Protection category	Relative strength
Norgestrel composition of matter	Very low; historically expired
Conventional immediate-release tablet	Very low
Low-dose blend process	Moderate only if narrowly claimed and non-obvious
Modified-release formulation	Potentially moderate, but commercially less aligned with current use
OTC labeling and consumer-use data	Regulatory advantage, not broad patent exclusivity
Packaging and adherence system	Potentially moderate, usually narrow
Manufacturing know-how	Potentially valuable but protected as trade secret

The best defensible positions are likely to be process know-how, supply-chain control, validated low-dose blending, and consumer-facing packaging rather than broad pharmaceutical composition claims.

What generic launch scenarios exist for norgestrel?

Three launch scenarios are commercially plausible.

Prescription generic launch

A manufacturer could pursue a conventional approved oral tablet for prescription distribution. The product would compete primarily on price, wholesaler access, and payer placement.

OTC challenger

An OTC challenger would need to satisfy FDA requirements for nonprescription use, including consumer comprehension, labeling, self-selection, and safe use without a prescriber. This pathway is more expensive than simply producing a prescription generic, but it offers access to the larger consumer-health channel.

Private-label or co-branded product

A retailer, digital health company, or consumer-health brand could use a contract manufacturer to commercialize an equivalent norgestrel tablet. The principal barriers would be FDA approval, supply reliability, packaging, and brand investment.

What litigation and licensing issues affect norgestrel?

There is no broad biosimilar litigation pathway because norgestrel is a small molecule. Potential disputes would involve:

• ANDA Paragraph IV certifications.
• Patent infringement claims covering a formulation or manufacturing process.
• Trade-secret disputes involving low-dose blending or scale-up.
• Trademark disputes involving product branding.
• Contract disputes involving API or finished-dose supply.
• Regulatory disputes over OTC labeling or application rights.

Perrigo acquired HRA Pharma in 2022, expanding Perrigo’s consumer-health portfolio and bringing Opill into its business.[5] Publicly disclosed information identifies the transaction as the principal commercial event behind Perrigo’s U.S. Opill position. No widely reported standalone licensing structure creates a broad barrier to third-party norgestrel development.

Key Takeaways

• Norgestrel is a mature small-molecule progestin with no biosimilar risk.
• The principal U.S. product is Perrigo’s Opill 0.075 mg OTC tablet.
• The reference excipient system uses lactose monohydrate, microcrystalline cellulose, pregelatinized starch, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate.
• Low-dose content uniformity is the central formulation challenge.
• Direct compression is the most commercially efficient platform when powder flow and segregation are controlled.
• Broad active-ingredient patent protection has expired; current risk is product- and application-specific.
• The strongest commercial opportunities are private-label supply, excipient substitution, packaging, OTC distribution, and manufacturing-cost reduction.
• FDA OTC conversion increases commercial value but does not restore new chemical entity exclusivity.
• Generic entry is more likely to be constrained by regulatory execution and retail access than by basic norgestrel patent claims.

FAQs

Can norgestrel be formulated without lactose?

Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, co-processed excipients, or other suitable diluents. The substitute must maintain content uniformity, dissolution, stability, and acceptable tablet properties.

Is norgestrel suitable for a chewable or orally disintegrating tablet?

Potentially. A chewable or orally disintegrating format could improve administration and create a differentiated product, but taste masking, dose uniformity, mechanical strength, moisture sensitivity, and consumer acceptability would require separate development work.

Does norgestrel require a solid dispersion or amorphous formulation?

Usually not for a conventional immediate-release tablet. The dose is very low, and the primary development problem is uniform distribution rather than delivering a poorly soluble drug at a high dose.

Can a company sell an OTC norgestrel product without copying Opill?

Yes, but the company would need an approved FDA pathway and compliant nonprescription labeling. It could use a different excipient system, tablet design, package, manufacturer, or brand, subject to regulatory requirements and any valid product-specific patent rights.

What is the highest-value excipient innovation for norgestrel?

A co-processed or engineered excipient system that improves low-dose blend uniformity while preserving rapid dissolution and reducing manufacturing steps would have the clearest value proposition. The commercial case would depend on measurable yield, scale-up, or supply-chain benefits.

References

1. U.S. Food and Drug Administration. (2023). Opill (norgestrel) tablets, 0.075 mg: Prescribing information.
2. U.S. Food and Drug Administration. (2023, July 13). FDA approves first nonprescription daily oral contraceptive.
3. Perrigo Company plc. (2024). Opill product and commercial launch information.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. Perrigo Company plc. (2022). Perrigo completes acquisition of HRA Pharma.